体軸型脊椎関節炎患者におけるイキセキズマブ休薬後の再治療と反応率: プラセボ対照休薬試験の104週結果
Ann Rheum Dis. 2022 doi: 10.1136/ard-2022-222731
The present analysis demonstrated that patients continuously treated with IXE were less likely to experience flare compared with patients receiving placebo. The aim of this study was to evaluate the recapture of response with open-label IXE retreatment at week 104 in patients with axSpA who flared after withdrawal of IXE therapy.